Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Medicine (Baltimore) ; 101(33): e30071, 2022 Aug 19.
Artículo en Inglés | MEDLINE | ID: covidwho-2001505

RESUMEN

RATIONALE: Diffuse alveolar hemorrhage (DAH) is a rare manifestation of childhood systemic lupus erythematosus (SLE) that can be life-threatening. Several reports have linked previous or concurrent coronavirus disease (COVID-19) infections with a high prevalence of autoimmune and autoinflammatory disorders. PATIENT CONCERNS: We report a case of a 13-year-old female who presented with DAH due to SLE 2 months after a laboratory-confirmed severe COVID-19 infection. DIAGNOSES: The patient was diagnosed with DAH due to SLE 2 months after a laboratory-confirmed severe COVID-19 infection. INTERVENTIONS AND OUTCOMES: The patient was treated with intravenous methylprednisolone pulse, broad-spectrum antibiotics, and supportive measures. In addition, she received 6 sessions of plasma exchange and maintenance methylprednisolone therapy (2 mg/kg/day). The patient then improved and was discharged on prednisolone, hydroxychloroquine, and azathioprine. LESSONS: We suggest plasmapheresis be considered a treatment for SLE-associated DAH in the context of active disease when conventional treatment has failed to induce a rapid response. In addition, further studies are needed to assess the role of COVID-19 as an autoimmune disease trigger, particularly for SLE.


Asunto(s)
COVID-19 , Enfermedades Pulmonares , Lupus Eritematoso Sistémico , Adolescente , COVID-19/complicaciones , COVID-19/terapia , Niño , Femenino , Hemorragia/diagnóstico , Hemorragia/etiología , Hemorragia/terapia , Humanos , Enfermedades Pulmonares/etiología , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/terapia , Metilprednisolona/uso terapéutico , Alveolos Pulmonares
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA